3344 Relationship between pembrolizumab exposure and efficacy/safety in 1016 patients (pts) with advanced or metastatic melanoma
Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anna Kondic(Merck & Co., Inc., Rahway, NJ, USA (United States)), David C. Turner, Jeroen Elassaiss‐Schaap(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kapil Mayawala(Merck & Co., Inc., Rahway, NJ, USA (United States)), Manash Chatterjee(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Stone, Malidi Ahamadi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Donald De Alwis, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rik de Greef(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tomoko Freshwater(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 3
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k